Registry for Pulmonary Hypertension Due to Left Heart Disease in China
NCT ID: NCT02164526
Last Updated: 2017-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
520 participants
OBSERVATIONAL
2013-01-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Registry for Pulmonary Hypertension in China
NCT01417338
Registry for Chronic Obstructive Pulmonary Disease With Pulmonary Hypertension in China
NCT03185572
Evaluation of the Progression of Disease and Health-related Quality of Life in Patients With Pulmonary Hypertension: A Local Clinic-based Registry
NCT06703801
Pulmonary Vasculature and Right Heart Dysfunction in Chronic Obstructive Pulmonay Disease
NCT03184727
PH-DyPred: A Multimodal Dynamic Risk Prediction Study in Pulmonary Hypertension
NCT07131241
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No treatment
Routine therapy
Routine therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Routine therapy
Routine therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Heart failure due to valvular heart disease
* Hypertrophic obstructive cardiomyopathy
* Right ventricular outflow tract stenosis
* Pericardial disease
* Patients with chronic lung disease
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese Academy of Medical Sciences, Fuwai Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jianguo He
Director of Pulmonary vascular disease center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Huang L, Pang L, Gu Q, Yang T, Li W, Quan R, Su W, Wu W, Tang F, Zhu X, Shen J, Sun J, Shan G, Xiong C, Huang S, He J. Prevalence, risk factors, and survival associated with pulmonary hypertension and heart failure among patients with underlying coronary artery disease: a national prospective, multicenter registry study in China. Chin Med J (Engl). 2022 Aug 5;135(15):1837-1845. doi: 10.1097/CM9.0000000000002112.
Lin Y, Pang L, Huang S, Shen J, Wu W, Tang F, Su W, Zhu X, Sun J, Quan R, Yang T, Han H, He J. Impact of borderline pulmonary hypertension due to left heart failure on mortality in a multicenter registry study: A 3-year survivorship analysis. Front Cardiovasc Med. 2022 Aug 12;9:983803. doi: 10.3389/fcvm.2022.983803. eCollection 2022.
Quan R, Huang S, Pang L, Shen J, Wu W, Tang F, Zhu X, Su W, Sun J, Yu Z, Wang L, Zhu X, Xiong C, He J. Risk prediction in pulmonary hypertension due to chronic heart failure: incremental prognostic value of pulmonary hemodynamics. BMC Cardiovasc Disord. 2022 Feb 16;22(1):56. doi: 10.1186/s12872-022-02492-1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRPHDLHD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.